{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/386344813"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "Adverse events including bleeding did not differ between the groups (103).A 2012 randomized, controlled trial compared aspirin, 100 mg/d, to placebo in 822 patients who had completed therapy for a first episode of unprovoked VTE. After 37 months follow-up, there was a nonsignificant trend toward reduced recurrent VTE in the aspirin group (6.5% in the placebo group vs. 4.8% in the aspirin group, P=" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "acponline.org" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/360441850"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/386344813"] } } }
